Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease-Reference-Cited by-同舟云学术

Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease

Published:2021-05-24 Issue:11 Volume:64 Page:7241-7260
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Grand Darren Le¹,Gosling Martin¹,Baettig Urs¹,Bahra Parmjit¹,Bala Kamlesh¹,Brocklehurst Cara²^ORCID,Budd Emma¹,Butler Rebecca¹,Cheung Atwood K.³^ORCID,Choudhury Hedaythul¹,Collingwood Stephen P.¹,Cox Brian¹^ORCID,Danahay Henry¹,Edwards Lee¹^ORCID,Everatt Brian¹,Glaenzel Ulrike²,Glotin Anne-Lise¹,Groot-Kormelink Paul²,Hall Edward³,Hatto Julia¹,Howsham Catherine¹,Hughes Glyn¹,King Anna¹,Koehler Julia²,Kulkarni Swarupa⁴,Lightfoot Megan¹,Nicholls Ian²,Page Christopher¹,Pergl-Wilson Giles¹,Popa Mariana Oana¹,Robinson Richard³^ORCID,Rowlands David³,Sharp Tom¹,Spendiff Matthew¹,Stanley Emily¹,Steward Oliver¹,Taylor Roger J.¹,Tranter Pamela¹,Wagner Trixie²,Watson Hazel¹,Williams Gareth²,Wright Penny¹,Young Alice¹,Sandham David A.³^ORCID

Affiliation:

1. Novartis Institutes for Biomedical Research, Horsham Research Center, Wimblehurst Road, Horsham RH12 5AB, U.K.

2. Novartis Institutes for Biomedical Research, Novartis Campus, Basel, CH 4002, Switzerland

3. Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, United States

4. Novartis Institutes for Biomedical Research, East Hanover, New Jersey 07936, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00343

Reference51 articles.

1. About cystic fibrosis. Cystic Fibrosis Foundation: Bethesda, MD, 2017; https://www.cff.org/What-is-CF/About-Cystic-Fibrosis (accessed April 1, 2021).

2. Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA

3. Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways

4. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives

5. Discovery of N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a Potent and Orally Bioavailable CFTR Potentiator

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cells;Respiratory Research;2024-07-10

2. An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs;Nature Communications;2024-07-08

3. Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cells;2024-03-04

4. Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms;European Journal of Medicinal Chemistry;2024-02

5. Concentration‐QTcF Modeling of Icenticaftor from a Randomized, Placebo‐ and Positive‐Controlled Thorough QT Study in Healthy Participants;Clinical Pharmacology in Drug Development;2024-01-29